Why Is AEON Stock Rising Today? AEON Biopharma Shares Surge After Positive ABP-450 Study Data

AEON Biopharma (AEON) shares surged 40.04% in intraday trading after the company announced positive results from a pilot forced degradation study comparing its ABP-450 biosimilar candidate to BOTOX.

The study adds to the analytical evidence supporting the products' structural comparability, a key requirement under the FDA's 351(k) biosimilar pathway.

What Did The Pilot Study Show?

On September 9, AEON Biopharma released the results of a pilot forced degradation study distributed via GlobeNewswire. The testing subjected both ABP-450 and BOTOX to thermal and oxidative stress, assessing how each molecule held up under duress.

Under thermal stress, both products lost potency at comparable rates, with each reaching approximately half of initial observed potency by day 14, based on an LD50 assay. Under oxidative stress, the two products showed similar dose-dependent oxidation patterns at evaluated methionine sites, as measured by mass spectrometry peptide mapping.

Forced degradation testing is a standard analytical tool in biosimilar development. The stronger the analytical comparability data, the fewer additional studies regulators typically require.

The company noted the pilot study was not powered for formal statistical comparison. The findings establish the scientific basis for the planned multi-lot comparability study, the next major analytical step.

Why Does The ABP-450 Data Matter?

AEON Biopharma is pursuing full-label access to the U.S. therapeutic neurotoxin market, which exceeds $3 billion annually. ABP-450 is the same botulinum toxin type A complex already approved and marketed by Evolus under the brand name Jeuveau for cosmetic indications.

The key distinction here is that AEON is targeting therapeutic use rather than cosmetic applications. The therapeutic indications — spasticity, chronic migraine, and cervical dystonia — represent a substantially larger revenue pool than the cosmetic-only pathway that Jeuveau has pursued.

Manufacturing is already in place. ABP-450 is produced by Daewoong Pharmaceutical in a facility authorized by the U.S. FDA, Health Canada, and the European Medicines Agency for manufacturing certain third-party products. That regulatory history with the manufacturing site could streamline the BLA review process.

Still, forced degradation results are an analytical milestone, not a clinical one. The multi-lot comparability study remains ahead, and FDA approval for a biosimilar to an established reference product like BOTOX will face rigorous scrutiny.

What Should Investors Watch Next?

The multi-lot comparability study is the immediate next step. Its outcome will determine whether the analytical evidence package is sufficient to support a Biologics License Application submission to the FDA.

AEON management is hosting one-on-one investor meetings at the Lake Street Capital Markets 10th Annual Best Ideas Growth Conference in New York City on September 10, 2026. Updates on the development timeline or regulatory strategy could emerge from those discussions.

Patent and litigation risk around the BOTOX franchise is another consideration. Allergan has historically defended its intellectual property aggressively, and biosimilar entrants often face legal challenges alongside regulatory ones.

Trading volume was significantly elevated, running at roughly 17.7 times the 20-day average. That level of participation suggests broad market interest in the data, though investors will watch whether the momentum holds as the regulatory timeline comes into sharper focus.